Fig. 7

The effect of combination of IM and Baicalein on the leukemogenic activity engrafted with CML CD34⁺ cells in vivo. A K562 CD34⁺ cells (2 × 10⁶ cells per mouse) were transplanted into NOD/SCID mice, and then engraftments were randomly divided into four groups respectively. The animals engrafted with CD34⁺ cells were treated with or without IM (200 mg/kg), combination with or without Baicalein (20 mg/kg) (four groups, 5 mice/per group: media control(DMSO); Baicalein; IM; Baicalein + IM). Mice were performed with death after 6 weeks, and bone marrow contents were obtained. B Flow cytometry graphs showed that the levels of human CML CD45⁺ cells were regenerated in the BM of mice engrafted with K562 CD34 + cells treated with different drugs at 6 weeks. C Images of spleen were obtained from mice in each group. (D) Weight of spleen were examined and analyzed, **p < 0.01, ***p < 0.001 versus control group (DMSO); ^##p < 0.01 versus IM group. E The serial sections of spleens were examined for H&E staining. F The levels of human CML CD34⁺, CD33⁺, and CD19⁺ cells regenerated in the BM of mice engrafted with K562 CD34⁺ cells treated with different drugs were measured at 6 weeks. G The expressions of BCR-ABL mRNA obtained from selected CD45 + cells in BM were measured by qRT-PCR and normalized to GAPDH mRNA levels. H GM-CSF secretion in the supernatant of BM was evaluated. I The effect of Baicalein on JAK2/STAT5 signaling pathway was observed by Western blot from BM CML cells of mice. All data from independent experiments are presented as means ± SD. Significance values: **p < 0.01,***p < 0.001 versus control group; ^##p < 0.01 versus IM group